Statin therapy is generally well tolerated and very effective in the prevention and treatment of
cardiovascular disease, regardless of cholesterol levels; however, it can be associated with …

The discovery of bioactive molecules is an expensive and time-consuming process and new
strategies are continuously searched for in order to optimize this process. Virtual Screening …

Background Lipid-lowering therapy with statins and proprotein convertase subtilisin/kexin
type 9 (PCSK9) inhibition are effective strategies in reducing cardiovascular disease risk; …

The gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and its protein
product have been widely studied for their role in cholesterol and lipid metabolism. PCSK9 …

Introduction: Scientific evidence on subjects treated with statin or other lipid-lowering
treatments has established that treatments aiming to lower low-density lipoprotein …

Since the discovery of the role of proprotein convertase subtilisin kexin 9 (PCSK9) in the
regulation of low-density lipoprotein cholesterol (LDL-C) in 2003, a paradigm shift in the …

The advent of monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9
(PCSK9) ushered in a new era of dyslipidemia pharmacotherapy. The first two antibodies …

Background: Atherosclerotic cardiovascular disease remains a major cause of death and
disability, especially for high-risk familial hypercholesterolemia individuals. PCSK9i …

(LDL-C) are well established to be associated with the development of atherosclerotic
cardiovascular disease (ASCVD), defined as acute coronary syndrome, a history of …

Atherosclerosis is a multifactorial, progressive, chronic inflammatory disease. Ultrasound
and magnetic resonance imaging are the most accurate predictors of atherosclerotic plaque …